Mainz Biomed

Mainz Biomed OCF Margin

The Operating Cash Flow Margin of Mainz Biomed (MYNZ) as of Oct 30, 2026 is -2,044.31 %. In the previous year, Operating Cash Flow Margin was -1,911.65 % — a change of 6.94% (lower).

OCF Margin

-2,044.31 %

YoY

6.94%

Last updated:

Operating Cash Flow Margin of Mainz Biomed is 2025 -2,044.31 % . Operating Cash Flow Margin of Mainz Biomed was 2024 -1,911.65 % . It decreases by 6.94% lower compared to the previous year.

The Mainz Biomed OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2019
-148.01 USD
Jan 1, 2020
-94.97 USD
Jan 1, 2021
-557.78 USD
Jan 1, 2022
-2,787.36 USD
Jan 1, 2023
-2,449.96 USD
Jan 1, 2024
-1,911.65 USD
Jan 1, 2025
-2,044.31 USD
The Mainz Biomed OCF Margin history
YEAROCF MarginYoY
-2,044.31 %+6.94%
-1,911.65 %-21.97%
-2,449.96 %-12.10%
-2,787.36 %+399.73%
-557.78 %+487.32%
-94.97 %-35.84%
-148.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mainz Biomed Stock analysis

What does Mainz Biomed do? Mainz Biomed NV generates revenue through its genetic diagnostic testing services segment, offering products like ColoAlert, a stool-based DNA test for colorectal cancer screening, and PancAlert, a stool-based test for pancreatic cancer detection. The company also provides GenoStrip, a platform technology for molecular genetic pathogen detection in environments. Its primary customers include healthcare providers and diagnostic laboratories seeking advanced cancer screening solutions. Mainz Biomed competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc., and Agena Biosciences Inc. in the molecular genetics diagnostics market. The firm's product portfolio targets specific cancer types with non-invasive screening methods, focusing on colorectal and pancreatic cancers. ColoAlert and PancAlert are designed for early detection, while GenoStrip serves environmental pathogen monitoring. Mainz Biomed's revenue streams derive from the sale of these diagnostic tests and platform technology to healthcare institutions and laboratories. Mainz Biomed's business model centers on developing and commercializing molecular genetic diagnostic tools, with ColoAlert and PancAlert as key revenue drivers. The company's competitors in the diagnostics sector include Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc., and Agena Biosciences Inc., indicating a market focused on innovative cancer screening technologies. Mainz Biomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mainz Biomed stock

Operating Cash Flow Margin of Mainz Biomed is -2,044.31 % in 2025.

Operating Cash Flow Margin of Mainz Biomed changed from -1,911.65 % to -2,044.31 %, representing a 6.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Mainz Biomed since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Mainz Biomed with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Mainz Biomed

All Key Metrics — Mainz Biomed